Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 322

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Liu, Li, Bai, Xue, Wang, Jian, Tang, Xin-Ran, Wu, De-Hua, Du, Sha-Sha, Du, Xiu-Ju, Zhang, Yao-Wei, Zhu, Hong-Bo, Fang, Yuan, Guo, Ze-Qin, Zeng, Qin, Guo, Xue-Jun, Liu, Zhu, Dong, Zhong-Yi·2019·Clinical Cancer Research

Abstract

Purpose: Although tumor mutation burden (TMB) has been well known to predict the response to immune checkpoint inhibitors (ICI), lack of randomized clinical trial data has restricted its clinical application. This study aimed to explore the significance and feasibility of biomarker combination based on TMB and copy-number alteration (CNA) for the prognosis of each tumor and prediction for ICI therapy in metastatic pan-cancer milieu. Experimental Design: Non-ICI–treated MSK pan-cancer cohort was used for prognosis analysis. Three independent immunotherapy cohorts, including non–small cell lung cancer (n = 240), skin cutaneous melanoma (n = 174), and mixed cancer (Dana-Farber, n = 98) patients from previous studies, were analyzed for efficacy of ICI therapy. Results: TMB and CNA showed optimized combination for the prognosis of most metastatic cancer types, and patients with TMBlowCNAlow showed better survival. In the predictive analysis, both TMB and CNA were independent predictive factors for ICI therapy. Remarkably, when TMB and CNA were jointly analyzed, those with TMBhighCNAlow showed favorable responses to ICI therapy. Meanwhile, TMBhighCNAlow as a new biomarker showed better prediction for ICI efficacy compared with either TMB-high or CNA-low alone. Furthermore, analysis of the non-ICI–treated MSK pan-cancer cohort supported that the joint stratification of TMB and CNA can be used to categorize tumors into distinct sensitivity to ICI therapy across pan-tumors. Conclusions: The combination of TMB and CNA can jointly stratify multiple metastatic tumors into groups with different prognosis and heterogeneous clinical responses to ICI treatment. Patients with TMBhighCNAlow cancer can be an optimal subgroup for ICI therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-0558

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 322

Metadata

Authors
Liu, L., Bai, X., Wang, J., Tang, X.-R., Wu, D.-H., Du, S.-S., Du, X.-J., Zhang, Y.-W., Zhu, H.-B., Fang, Y., Guo, Z.-Q., Zeng, Q., Guo, X.-J., Liu, Z., & Dong, Z.-Y.
Venue
Clinical Cancer Research
Published
2019-12-13
Volume
25
Issue
24
Pages
7413-7423
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3002662929
Cited by
322
References
34
FWCI
12.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0558
The paper
Liu, L., Bai, X., Wang, J., Tang, X.-R., Wu, D.-H., Du, S.-S., Du, X.-J., Zhang, Y.-W., Zhu, H.-B., Fang, Y., Guo, Z.-Q., Zeng, Q., Guo, X.-J., Liu, Z., & Dong, Z.-Y. (2019). Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0558

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.